Cargando…
Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
BACKGROUND: Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent. OBJECTIVE: We examined the effects of Bifidobacterium animalis su...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492721/ https://www.ncbi.nlm.nih.gov/pubmed/28662676 http://dx.doi.org/10.1186/s12937-017-0261-6 |
_version_ | 1783247387404271616 |
---|---|
author | Lee, Yujin Ba, Zhaoyong Roberts, Robert F. Rogers, Connie J. Fleming, Jennifer A. Meng, Huicui Furumoto, Emily J. Kris-Etherton, Penny M. |
author_facet | Lee, Yujin Ba, Zhaoyong Roberts, Robert F. Rogers, Connie J. Fleming, Jennifer A. Meng, Huicui Furumoto, Emily J. Kris-Etherton, Penny M. |
author_sort | Lee, Yujin |
collection | PubMed |
description | BACKGROUND: Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent. OBJECTIVE: We examined the effects of Bifidobacterium animalis subsp. lactis BB-12(®) (BB-12(®)) (3.16 × 10(9) CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults. METHODS: In a randomized, partially blinded, 4-period, crossover study, 30 adults (11 men, 19 women) aged 18–40 years were randomly assigned to: 1) yogurt smoothie with no BB-12(®) (YS), 2) yogurt smoothie with BB-12(®) added pre-fermentation (PRE), 3) yogurt smoothie with BB-12(®) added post-fermentation (POST), 4) BB-12(®) containing capsule (CAP). We measured serum lipids/lipoproteins, glucose, insulin, C-reactive protein (CRP), and fecal SCFAs at baseline and after each treatment period. RESULTS: Total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TGs) did not differ after the PRE, POST, and CAP periods versus the YS or between treatments. Compared to baseline, fecal acetate was significantly increased after the YS (Δ = 211.89 ± 75.87 μg/g, P = 0.007) and PRE (Δ = 204.98 ± 75.70 μg/g, P = 0.009) periods. The percent increase in fecal acetate was significantly greater after the YS versus the POST period (52.2 ± 13.2% vs. 24.5 ± 13.2%, P = 0.023). Fecal total SCFAs, propionate and butyrate did not differ between treatment periods. Fecal total SCFAs were negatively associated with TC (r = -0.22, P = 0.01), LDL-C (r = -0.24, P = 0.004), age (r = -0.33, P < 0.001), and waist circumference (r = -0.25, P = 0.003). CONCLUSIONS: BB-12(®) supplementation did not improve lipids, lipoproteins and total and individual fecal SCFAs. Fecal SCFAs were negatively associated with TC, LDL-C, age, and waist circumference. TRIAL REGISTRATION: This trial was registered at clinicaltrials.gov as NCT01399996. |
format | Online Article Text |
id | pubmed-5492721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54927212017-06-30 Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial Lee, Yujin Ba, Zhaoyong Roberts, Robert F. Rogers, Connie J. Fleming, Jennifer A. Meng, Huicui Furumoto, Emily J. Kris-Etherton, Penny M. Nutr J Research BACKGROUND: Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent. OBJECTIVE: We examined the effects of Bifidobacterium animalis subsp. lactis BB-12(®) (BB-12(®)) (3.16 × 10(9) CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults. METHODS: In a randomized, partially blinded, 4-period, crossover study, 30 adults (11 men, 19 women) aged 18–40 years were randomly assigned to: 1) yogurt smoothie with no BB-12(®) (YS), 2) yogurt smoothie with BB-12(®) added pre-fermentation (PRE), 3) yogurt smoothie with BB-12(®) added post-fermentation (POST), 4) BB-12(®) containing capsule (CAP). We measured serum lipids/lipoproteins, glucose, insulin, C-reactive protein (CRP), and fecal SCFAs at baseline and after each treatment period. RESULTS: Total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TGs) did not differ after the PRE, POST, and CAP periods versus the YS or between treatments. Compared to baseline, fecal acetate was significantly increased after the YS (Δ = 211.89 ± 75.87 μg/g, P = 0.007) and PRE (Δ = 204.98 ± 75.70 μg/g, P = 0.009) periods. The percent increase in fecal acetate was significantly greater after the YS versus the POST period (52.2 ± 13.2% vs. 24.5 ± 13.2%, P = 0.023). Fecal total SCFAs, propionate and butyrate did not differ between treatment periods. Fecal total SCFAs were negatively associated with TC (r = -0.22, P = 0.01), LDL-C (r = -0.24, P = 0.004), age (r = -0.33, P < 0.001), and waist circumference (r = -0.25, P = 0.003). CONCLUSIONS: BB-12(®) supplementation did not improve lipids, lipoproteins and total and individual fecal SCFAs. Fecal SCFAs were negatively associated with TC, LDL-C, age, and waist circumference. TRIAL REGISTRATION: This trial was registered at clinicaltrials.gov as NCT01399996. BioMed Central 2017-06-29 /pmc/articles/PMC5492721/ /pubmed/28662676 http://dx.doi.org/10.1186/s12937-017-0261-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Lee, Yujin Ba, Zhaoyong Roberts, Robert F. Rogers, Connie J. Fleming, Jennifer A. Meng, Huicui Furumoto, Emily J. Kris-Etherton, Penny M. Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial |
title | Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial |
title_full | Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial |
title_fullStr | Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial |
title_full_unstemmed | Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial |
title_short | Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial |
title_sort | effects of bifidobacterium animalis subsp. lactis bb-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492721/ https://www.ncbi.nlm.nih.gov/pubmed/28662676 http://dx.doi.org/10.1186/s12937-017-0261-6 |
work_keys_str_mv | AT leeyujin effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial AT bazhaoyong effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial AT robertsrobertf effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial AT rogersconniej effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial AT flemingjennifera effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial AT menghuicui effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial AT furumotoemilyj effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial AT krisethertonpennym effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial |